Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  European Journal of Cancer

• Publication date

  2005-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.EJCA.2005.03.005PMID 15939265
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials.

  2005cited by this paper
• Clinical Significance of Angiogenesis in Gastrointestinal Cancers: A Target for Novel Prognostic and Therapeutic Approaches

  2003cited by this paper
• PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.

  2002cited by this paper
• Antiangiogenesis: Current Clinical Data and Future Perspectives

  2002cited by this paper
• Mechanisms and future directions for angiogenesis-based cancer therapies.

  2002cited by this paper
• PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

  2000cited by this paper
• Anti-angiogenesis therapy:concepts and importance of dosing schedules in clinical trials.

  2000cited by this paper
• Vascular endothelial growth factor (VEGF) and its receptors

  1999cited by this paper
• Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

  1998cited by this paper
• Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine.

  1997cited by this paper
• Myocardial perfusion modeling using MRI

  1996cited by this paper
• Patterns and Emerging Mechanisms Review of the Angiogenic Switch during Tumorigenesis

  1996cited by this paper
• Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression

  1995cited by this paper
• Tumour blood flow: measurement and manipulation for therapeutic gain.

  1993cited by this paper
• Vascular permeability factor (VPF, VEGF) in tumor biology

  1993cited by this paper
• Molecular and biological properties of the vascular endothelial growth factor family of proteins.

  1992cited by this paper
• Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

  1992cited by this paper
• Tumor invasion and metastases: biochemical mechanisms.

  1988cited by this paper
• Tumor angiogenesis: therapeutic implications.

  1971cited by this paper

• New vatalanib analogs: design, synthesis, in silico study and biological evaluation for anticancer activity

  2024cites this paper
• Platform combining statistical modeling and patient-derived organoids to facilitate personalized treatment of colorectal carcinoma

  2023cites this paper
• Magnetic Resonance Imaging for Drug Development.

  2021cites this paper
• The Prowess of Andrographolide as a Natural Weapon in the War against Cancer

  2020cites this paper
• Tumor Biology Characterization by Imaging in Laboratory

  2020cites this paper
• A Comparative Study of Two-Compartment Exchange Models for Dynamic Contrast-Enhanced MRI in Characterizing Uterine Cervical Carcinoma

  2019cites this paper
• Quantitative perfusion imaging of neoplastic liver lesions: A multi-institution study

  2018cites this paper
• Angiogenesis: Managing the Culprits behind Tumorigenesis and Metastasis

  2018cites this paper
• Vascular mimicry in glioblastoma following anti-angiogenic and anti-20-HETE therapies.

  2017cites this paper
• Quantitative magnetic resonance imaging biomarkers in oncological clinical trials: Current techniques and standardization challenges

  2017cites this paper
• Therapeutic Agents That Inhibit Angiogenesis

  2017cites this paper
• Receptor tyrosine kinase inhibitors: Are they real tumor killers?

  2016cites this paper
• Dynamic contrast‐enhanced MRI for oncology drug development

  2016cites this paper
• Dual-pH responsive micelle platform for co-delivery of axitinib and doxorubicin.

  2016cites this paper
• Evaluating the effectiveness of Endostar therapy in human lung cancer xenografts using contrast-enhanced magnetic resonance imaging

  2016cites this paper
• Assessment of Tumor Angiogenesis: Dynamic Contrast-enhanced MR Imaging and Beyond.

  2016cites this paper
• Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.

  2015cites this paper
• Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors

  2015influential citation
• An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer

  2015cites this paper
• Angiogenesis in myeloproliferative neoplasms, new markers and future directions

  2014cites this paper
• Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis

  2014cites this paper
• Preclinical Evaluation of Oral Metronomic Topotecan and Pazopanib for the Treatment of Aggressive Extracranial Pediatric Solid Tumors

  2014cites this paper
• European perspective for effective cancer drug development

  2014cites this paper
• Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance).

  2014cites this paper
• Perfusion imaging in liver MRI.

  2014cites this paper
• DCE-MRI assessment of the effect of Epstein-Barr virus-encoded latent membrane protein-1 targeted DNAzyme on tumor vasculature in patients with nasopharyngeal carcinomas

  2014cites this paper
• Picture the future: emerging imaging modalities.

  2014cites this paper
• Dynamic contrast-enhanced magnetic resonance imaging studies in preclinical settings and beyond

  2014cites this paper
• Role of tumour angiogenesis in haematological malignancies.

  2014cites this paper
• A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance)

  2013cites this paper
• Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma

  2013cites this paper
• INTRODUCTION TO MOLECULAR IMAGING

  2013cites this paper
• Quantitative MRI of Tumors

  2013cites this paper
• Population pharmacokinetics and exposure toxicity analysis of Vatalanib in patients with myelodysplastic syndromes

  2013influential citation
• Newer Agents in Colon Cancer: What’s Next?

  2013cites this paper
• Bioanalysis and clinical pharmacology of tyrosine kinase inhibitors

  2013cites this paper
• First-in-Human Phase I Study of PRS-050 (Angiocal), an Anticalin Targeting and Antagonizing VEGF-A, in Patients with Advanced Solid Tumors

  2013cites this paper
• Advanced MR techniques in multicenter clinical trials

  2013cites this paper
• Emerging VEGF-receptor inhibitors for colorectal cancer

  2013cites this paper
• The future of clinical research in oncology: where are we heading to?

  2013cites this paper
• Academia-industry partnerships: are we ready for new models of partnership?: the point of view of the EORTC, an academic clinical cancer research organisation.

  2013cites this paper
• Improving the Diagnosis and Management of Neuroendocrine Tumors: Utilizing New Advances in Biomarker and Molecular Imaging Science

  2013cites this paper
• Functional imaging of the liver.

  2013cites this paper
• Radiolabeled RGD peptides as integrin alpha(v)beta3-targeted PET tracers.

  2012cites this paper
• The VEGF pathway in cancer and disease: responses, resistance, and the path forward.

  2012cites this paper
• Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer

  2012cites this paper
• Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC)

  2012cites this paper
• What does a modified-Fibonacci dose-escalation actually correspond to?

  2012cites this paper
• Pharmacokinetic parameters from 3‐Tesla DCE‐MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis

  2012cites this paper
• A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

  2012cites this paper
• Vascular Biomarkers and Imaging Studies

  2012cites this paper
• Angiogenesis in hepatocellular carcinoma: a potential target for chemoprevention and therapy.

  2012cites this paper
• Do Imaging Biomarkers Relate to Outcome in Patients Treated with VEGF Inhibitors?

  2012cites this paper
• Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis.

  2012cites this paper
• Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC).

  2012cites this paper
• Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies

  2012cites this paper
• Practical Dynamic Contrast Enhanced MRI in Small Animal Models of Cancer: Data Acquisition, Data Analysis, and Interpretation

  2012cites this paper
• Dynamic Contrast-Enhanced Magnetic Resonance Imaging

  2012cites this paper
• Die Rolle des VEGF im Ovarialkarzinom

  2011cites this paper
• Inhibitors of Tumor Angiogenesis

  2011cites this paper
• Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products.

  2011cites this paper
• Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.

  2011cites this paper
• Biomarkers in Tumor Angiogenesis and Anti-Angiogenic Therapy

  2011cites this paper
• Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma.

  2011cites this paper
• Lymphangioleiomyomatosis: what do we know and what are we looking for?

  2011cites this paper
• Incorporation of targeted agents in the management of patients with advanced gastric cancer.

  2011cites this paper
• A comparative study of dynamic contrast‐enhanced MRI parameters as biomarkers for anti‐angiogenic drug therapy

  2011cites this paper
• Quantitative DCE-MRI modeling on tumor diagnosis and treatment effect evaluation

  2011cites this paper
• Biomarkers of Anti-Angiogenic Therapy in Metastatic Colorectal Cancer (mCRC): Original Data and Review of the Literature

  2011cites this paper
• Vascular profile characterization of liver tumors by magnetic resonance imaging using hemodynamic response imaging in mice.

  2011cites this paper
• Liver cancer: Targeted future options.

  2011cites this paper
• Is VEGF a predictive biomarker to anti-angiogenic therapy?

  2011cites this paper
• Biomarkers in Tumor Angiogeneis and Anti-Angiogenic Therapy

  2011cites this paper
• Targeting Angiogenesis in the Treatment of Hepatic Metastasis

  2011cites this paper
• Quantifying Tumor Vascular Heterogeneity with Dynamic Contrast-Enhanced Magnetic Resonance Imaging: A Review

  2011cites this paper
• Clinical trials with anti-angiogenic agents in hematological malignancies

  2010cites this paper
• Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor

  2010cites this paper
• Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools?

  2010cites this paper
• A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer.

  2010cites this paper
• Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo

  2010cites this paper
• Quantitative MR in multi‐center clinical trials

  2010cites this paper
• Emergence of potential biomarkers of response to anti‐angiogenic anti‐tumour agents

  2010cites this paper
• Cellular and soluble markers of tumor angiogenesis: from patient selection to the identification of the most appropriate postresistance therapy.

  2010cites this paper
• Functional magnetic resonance imaging of the liver: parametric assessments beyond morphology.

  2010cites this paper
• Targeted therapy for gastrointestinal stromal tumors: current status and future perspectives

  2010cites this paper
• MRI to Assess Vascular Disruptive Agents

  2010cites this paper
• New Action of Inhibin Alpha Subunit in Advanced Prostate Cancer

  2010cites this paper
• Reviewtrials with anti-angiogenic agents in hematological malignancies

  2010cites this paper
• Imaging as a Localized Biomarker: Opportunities and Challenges

  2010cites this paper
• Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study

  2009cites this paper
• Accelerated Perinecrotic Outgrowth of Colorectal Liver Metastases Following Radiofrequency Ablation is a Hypoxia-Driven Phenomenon

  2009cites this paper
• Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.

  2009cites this paper
• The parametric response map is an imaging biomarker for early cancer treatment outcome

  2009cites this paper
• Dynamic contrast-enhanced magnetic resonance imaging parameters independent of baseline T10 values.

  2009cites this paper
• Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy.

  2009cites this paper
• Anti-angiogenic cancer therapy updates.

  2009cites this paper
• DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study

  2009cites this paper
• A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

  2009cites this paper
• Anti-angiogenic therapy against gastrointestinal tract cancers.

  2009cites this paper
• Biomarkers of angiogenesis and their role in the development of VEGF inhibitors

  2009influential citation